Keymed Biosciences Inc.
2162
Classifica tra le azioni
#4895
Keymed Biosciences Inc., a biotechnology firm founded in 2016 in Chengdu, China... Keymed Biosciences Inc., a biotechnology firm founded in 2016 in Chengdu, China (formerly known as 2Health Biosciences, Inc.), specializes in the research and development of innovative biological treatments, primarily targeting autoimmune and oncology diseases. A cornerstone of their pipeline is CM310, their lead product candidate, which is currently being developed for the management of moderate to severe atopic dermatitis (AD), asthma, chronic rhinosinusitis with nasal polyposis (CRSwNP), and chronic obstructive pulmonary disease (COPD). Complementing this, the company is also progressing CM326, a monoclonal antibody designed to inhibit thymic stromal lymphopoietin, for similar indications such as AD, CRSwNP, asthma, and COPD. In the realm of oncology, Keymed is developing CMG901 for solid tumors, particularly those affecting the stomach and gastroesophageal junction. Another significant candidate, CM313, is a humanized monoclonal antibody slated for the treatment of relapsed or refractory multiple myeloma, lymphoma, other blood cancers, and systemic lupus erythematosus. Their extensive portfolio further includes MIL95/CM312, a humanized monoclonal antibody targeting CD47; CM338, an antagonist antibody against mannose-binding lectin-associated serine protease-2; CM355, intended for relapsed or refractory non-Hodgkin's lymphoma; CM336, for multiple myeloma; CM350, for various solid tumors; and CM369, an anti-CC chemokine receptor 8 monoclonal antibody.
Prezzo delle azioni
$10.08
Capitalizzazione di mercato
$2.97B
Variazione (1 giorno)
-8.18%
Variazione (1 anno)
25.74%
Paese
CN
Scambia Keymed Biosciences Inc. (2162)
Categoria
Healthcare
Utile per Keymed Biosciences Inc. (2162)
Utile nel 2026 TTM: 0
Secondo gli ultimi rapporti finanziari di Keymed Biosciences Inc., gli utili attuali della società sono 0. Nel 2026, la società ha registrato un utile di 0, uguale a agli utili del 2026, che erano di 0. Gli utili mostrati in questa pagina sono quelli prima degli interessi e delle imposte, ovvero EBIT.
Storico degli utili di Keymed Biosciences Inc. dal 2019 al 2026
Utile alla fine di ogni anno
| Anno | Utile | Cambia |
|---|---|---|
| 2025 | $-72.50M | 4.04% |
| 2024 | $-69.69M | 38.49% |
| 2023 | $-50.32M | 14.33% |
| 2022 | $-44.01M | -92.81% |
| 2021 | $-612.44M | 388.60% |
| 2020 | $-125.35M | 421.05% |
| 2019 | $-24.06M | 0.00% |
Utile per aziende simili o concorrenti
| Azienda | Utile | Differenza negli utili | Il paese |
|---|---|---|---|
| $5.27B | - |
US
|
|
| $-3.09B | - |
US
|
|
| $-4.02B | - |
AU
|
|
| $1.95B | - |
NL
|
|
| - | - |
CH
|
